These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 11347050

  • 1. [Abnormal lipid metabolism in acromegaly].
    Inoue T.
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():162-6. PubMed ID: 11347050
    [No Abstract] [Full Text] [Related]

  • 2. [Hypertension in acromegaly].
    Kumagai H, Onami T, Iigaya K, Hayashi K, Saruta T.
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():508-11. PubMed ID: 15171425
    [No Abstract] [Full Text] [Related]

  • 3. The vascular complications of acromegaly.
    Bondanelli M, Zatelli MC, Ambrosio MR, degli Uberti EC.
    J Endocrinol Invest; 2003 Mar; 26(8 Suppl):28-31. PubMed ID: 15233208
    [No Abstract] [Full Text] [Related]

  • 4. The neoplastic complications of acromegaly.
    Terzolo M, Daffara F, Reimondo G, Allasino B, Ventura M, Angeli A.
    J Endocrinol Invest; 2003 Mar; 26(8 Suppl):32-4. PubMed ID: 15233209
    [No Abstract] [Full Text] [Related]

  • 5. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
    Esposito V, Esposito D, Lo Iudice G.
    Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
    [Abstract] [Full Text] [Related]

  • 6. [Hyperlipidemia in patients with GH deficiency].
    Hizuka N.
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():167-71. PubMed ID: 11347051
    [No Abstract] [Full Text] [Related]

  • 7. Less is more risky? Growth hormone and insulin-like growth factor 1 levels and cardiovascular risk.
    Maison P, Chanson P.
    Nat Clin Pract Endocrinol Metab; 2006 Dec; 2(12):650-1. PubMed ID: 17143307
    [No Abstract] [Full Text] [Related]

  • 8. Effects of octreotide on lipid metabolism in acromegaly.
    Cohen R, Chanson P, Bruckert E, Timsit J, Legrand A, Harris AG, Guillausseau PJ, Warnet A, Lubetzki J.
    Horm Metab Res; 1992 Aug; 24(8):397-400. PubMed ID: 1526629
    [Abstract] [Full Text] [Related]

  • 9. The GH-IGF-I axis and the cardiovascular system: clinical implications.
    Colao A.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):347-58. PubMed ID: 18462260
    [Abstract] [Full Text] [Related]

  • 10. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly.
    Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V, Merola B.
    J Endocrinol; 1997 Oct; 155 Suppl 1():S33-7; discussion S39. PubMed ID: 9389993
    [Abstract] [Full Text] [Related]

  • 11. Acromegaly: effects on bone metabolism and mass.
    Bogazzi F, Cosci C, Sardella C, Martino E, Gasperi M.
    J Endocrinol Invest; 2005 Oct; 28(10 Suppl):33-5. PubMed ID: 16550720
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 14. [Disturbances of lipid and lipoprotein metabolism in hypeprolactinemia and acromegaly].
    Medić-Stojanoska M, Pletikosić I.
    Med Pregl; 2009 Jun; 62 Suppl 3():91-4. PubMed ID: 19702124
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular complications in acromegaly.
    Vitale G, Pivonello R, Lombardi G, Colao A.
    Minerva Endocrinol; 2004 Sep; 29(3):77-88. PubMed ID: 15282442
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of the somatostatin analogue SMS 201-995 on faecal fat excretion in acromegaly.
    McGregor AR, Troughton WD, Donald RA, Espiner EA.
    Horm Metab Res; 1990 Jan; 22(1):55-6. PubMed ID: 1968417
    [No Abstract] [Full Text] [Related]

  • 18. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.
    Delaroudis SP, Efstathiadou ZA, Koukoulis GN, Kita MD, Farmakiotis D, Dara OG, Goulis DG, Makedou A, Makris P, Slavakis A, Avramides AI.
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):279-84. PubMed ID: 18194486
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.